secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARINUS PHARMACEUTICALS, INC. (—)
CIK:        0001267813
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001558370-24-007186
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marinus Q1 ZTALMY rev $7.5M (+125% YoY); cost cuts extend cash runway to Q1 2025; RAISE data summer
--------------------------------------------------------------------------------

- ZTALMY net product revenue $7.5M vs $3.3M YoY; full-year guidance raised to $33-35M from $32-34M.
- Phase 3 TrustTSC enrollment completes mid-May; topline data expected H1 Q4 2024; sNDA submission target April 2025.
- Phase 3 RAISE (IV ganaxolone in RSE) enrolled 100 patients; topline results early summer 2024; RAISE II stopped.
- Company reduced workforce ~20%, stopped RAISE/RAISE II enrollment, deferred IV ganaxolone manufacturing; cash $113.3M.
- Net loss $38.7M ($0.68/sh) vs $34.7M ($0.67/sh) in Q1 2023; total GAAP operating expenses guided $135-140M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267813/000155837024007186/0001558370-24-007186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267813/000155837024007186/mrns-20240508x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer